Citations

Mayo Clinic

Clear

1904 citation(s) found for "Yu, Frank".

De novo acute myeloid leukemia with 20–29% blasts is less aggressive than acute myeloid leukemia with ≥30% blasts in older adults: a Bone Marrow Pathology Group study
Hasserjian, Robert P. , Campigotto, Federico, Klepeis, Veronica, Fu, Bin , Wang, Sa A. , Bueso‐Ramos, Carlos E. , Cascio, Michael J. , Soderquist, Craig , Bagg, Adam , Yan, Jiong , Ochs, Rachel, Orazi, Attilio , Moore, Frank, Mahmoud, Amer, George, Tracy I. , Foucar, Kathryn , Odem, Jamie L., Booth, Cassie, Morice, William G. , Stone, Richard M. , Rogers, Heesun J. , Hsi, Eric D. , Morice, William George , DeAngelo, Daniel J. , Steensma, David P. , Neuberg, Donna , Arber, Daniel A. , Cascio, M J , George, Tracy I , Orazi, Attilio

American Journal of Hematology | July 17, 2014 | Volume: 89 | Issue: 11 | Pages: No page available

10.1002/ajh.23808 | PMID 25042343 Get It

It is controversial whether acute myeloid leukemia (AML) patients with 20–29% bone marrow (BM) blasts, formerly referred to as refractory anemia with excess blasts in transformation (RAEBT), should be considered AML or myelodysplastic syndrome (MDS) for the purposes of treatment and prognostication. We retrospectively studied 571 de novo AML in patients aged >50 years, including 142 RAEBT and 429 with ≥30% blasts (AML30), as well as 151 patients with 10–19% BM blasts (RAEB2). RAEBT patients were older and had lower white blood count, but higher hemoglobin, platelet count, and karyotype risk scores compared to AML30, while these features were similar to RAEB2. FLT3 and NPM1 mutations and monocytic morphology occurred more commonly in AML30 than in RAEBT. RAEBT patients were treated less often with induction therapy than AML30, whereas allogeneic stem cell transplant frequency was similar. The median and 4‐year OS of RAEBT patients were longer than those of AML30 patients (20.5 vs 12.0 months and 28.6% vs 20.4%, respectively, P = 0.003); this difference in OS was manifested in patients in the intermediate UKMRC karyotype risk group, whereas OS of RAEBT patients and AML30 patients in the adverse karyotype risk group were not significantly different. Multivariable analysis showed that RAEBT (P < 0.0001), hemoglobin (P = 0.005), UKMRC karyotype risk group (P = 0.002), normal BM karyotype (P = 0.004), treatment with induction therapy (P < 0.0001), and stem cell transplant (P < 0.0001) were associated with longer OS. Our findings favor considering de novo RAEBT as a favorable prognostic subgroup of AML. Am. J. Hematol. 89:E193–E199, 2014. © 2014 Wiley Periodicals, Inc.
Factors Associated with Adherence to an End-of-Study Biopsy: Lessons from the Prostate Cancer Prevention Trial (SWOG-Coordinated Intergroup Study S9217)
Gritz, Ellen R., Arnold, Kathryn B. , Moinpour, Carol M. , Burton‐Chase, Allison M. , Probstfield, Jeffrey F., See, William A., Lieber, Michael M., Caggiano, Vincent , Moody‐Thomas, Sarah, Szczepanek, Connie M. , Ryan, Anne, Carlin, Susie M., Hill, Shannon , Goodman, Phyllis J. , Padberg, Rose Mary, Minasian, Lori M. , Meyskens, Frank L. , Thompson, Ian M. , Tangen, Catherine M. , Thompson, Ian M

Cancer Epidemiology, Biomarkers & Prevention | July 16, 2014 | Volume: 23 | Issue: 8 | Pages: 1638-1648

10.1158/1055-9965.epi-14-0202 | PMID 25028457 Get It

Abstract Background: The Prostate Cancer Prevention Trial (PCPT) was a 7-year randomized, double-blind, placebo-controlled trial of the efficacy of finasteride for the prevention of prostate cancer with a primary outcome of histologically determined prevalence of prostate cancer at the end of 7 years. Methods: A systematic modeling process using logistic regression identified factors available at year 6 that are associated with end-of-study (EOS) biopsy adherence at year 7, stratified by whether participants were ever prompted for a prostate biopsy by year 6. Final models were evaluated for discrimination. At year 6, 13,590 men were available for analysis. Results: Participants were more likely to have the EOS biopsy if they were adherent to study visit schedules and procedures and/or were in good health (P &lt; 0.01). Participants at larger sites and/or sites that received retention and adherence grants were also more likely to have the EOS biopsy (P &lt; 0.05). Conclusions: Our results show good adherence to study requirements 1 year before the EOS biopsy was associated with greater odds that a participant would comply with the invasive EOS requirement. Impact: Monitoring adherence behaviors may identify participants at risk of nonadherence to more demanding study end points. Such information could help frame adherence intervention strategies in future trials. Cancer Epidemiol Biomarkers Prev; 23(8); 1638–48. ©2014 AACR.
Association of low numbers of CD 206‐positive cells with loss of ICC in the gastric body of patients with diabetic gastroparesis
Bernard, C, Gibbons, Simon J. , Mann, Inderjit, Froschauer, Lukas, Harbison, Sean, Snape, William J., McCallum, Richard W. , Sarosiek, Irene , Koch, Kenneth L. , Tonascia, James , Hamilton, Frank A., Kendrick, Michael L. , Shen, K. Robert , Pasricha, Pankaj J. , Farrugia, Gianrico , Parkman, Henry P. , Abell, Thomas L. , Hasler, William L. , Nguyen, Linda Anh B. , Gibbons, S J

Neurogastroenterology & Motility | July 15, 2014 | Volume: 26 | Issue: 9 | Pages: 1275-1284

10.1111/nmo.12389 | PMID 25041465 Get It

Abstract Background There is increasing evidence for specific cellular changes in the stomach of patients with diabetic ( DG ) and idiopathic ( IG ) gastroparesis. The most significant findings are loss of interstitial cells of Cajal ( ICC ), neuronal abnormalities, and an immune cellular infiltrate. Studies done in diabetic mice have shown a cytoprotective effect of CD 206+ M2 macrophages. To quantify overall immune cellular infiltrate, identify macrophage populations, and quantify CD 206+ and i NOS + cells. To investigate associations between cellular phenotypes and ICC . Methods Full thickness gastric body biopsies were obtained from non‐diabetic controls (C), diabetic controls ( DC ), DG , and IG patients. Sections were labeled for CD 45, CD 206, Kit, i NOS , and putative human macrophage markers ( HAM 56, CD 68, and EMR 1). Immunoreactive cells were quantified from the circular muscle layer. Key Results Significantly fewer ICC were detected in DG and IG tissues, but there were no differences in the numbers of cells immunoreactive for other markers between patient groups. There was a significant correlation between the number of CD 206+ cells and ICC in DG and DC patients, but not in C and IG and a significant correlation between i NOS + cells and ICC in the DC group, but not the other groups. CD 68 and HAM 56 reliably labeled the same cell populations, but EMR 1 labeled other cell types. Conclusions & Inferences Depletion of ICC and correlation with changes in CD 206+ cell numbers in DC and DG patients suggests that in humans, like mice, CD 206+ macrophages may play a cytoprotective role in diabetes. These findings may lead to novel therapeutic options, targeting alternatively activated macrophages.
At the interface of sensory and motor dysfunctions and Alzheimer's disease
Gilmore, Grover C. , Kaye, Jeffrey , Murphy, Claire , Wingfield, Arthur , Bennett, David A. , Boxer, Adam L. , Buchman, Aron S. , Cruickshanks, Karen J., Devanand, Davangere P. , Duffy, Charles J., Gates, George A., Holtzer, Roee , Lin, Frank R. , McKee, Ann C. , Morris, John C. , Petersen, Ronald C. , Silbert, Lisa C. , Struble, Robert G., Trojanowski, John Q. , Verghese, Joe , Xu, Shunbin , Albers, Mark W. , Gall, Christine M. , Granholm, Ann‐Charlotte , Hensch, Takao K. , Hyman, Bradley T. , Wilson, Donald A. , Zhang, Li I. , Bennett, David A. , Morris, John C

Alzheimer's & Dementia | July 8, 2014 | Volume: 11 | Issue: 1 | Pages: 70-98

10.1016/j.jalz.2014.04.514 | PMID 25022540 Get It

Abstract Recent evidence indicates that sensory and motor changes may precede the cognitive symptoms of Alzheimer's disease (AD) by several years and may signify increased risk of developing AD. Traditionally, sensory and motor dysfunctions in aging and AD have been studied separately. To ascertain the evidence supporting the relationship between age‐related changes in sensory and motor systems and the development of AD and to facilitate communication between several disciplines, the National Institute on Aging held an exploratory workshop titled “Sensory and Motor Dysfunctions in Aging and AD.” The scientific sessions of the workshop focused on age‐related and neuropathologic changes in the olfactory, visual, auditory, and motor systems, followed by extensive discussion and hypothesis generation related to the possible links among sensory, cognitive, and motor domains in aging and AD. Based on the data presented and discussed at this workshop, it is clear that sensory and motor regions of the central nervous system are affected by AD pathology and that interventions targeting amelioration of sensory‐motor deficits in AD may enhance patient function as AD progresses.
Pulmonary artery stents in the recent era
Ing, Frank F. , Khan, Asra , Kobayashi, Daisuke , Hagler, Donald J. , Forbes, Thomas J.

Catheterization and Cardiovascular Interventions | June 6, 2014 | Volume: 84 | Issue: 7 | Pages: 1123-1130

10.1002/ccd.25567 | PMID 24910458 Get It

BackgroundLong‐term follow‐up after stent dilation of native and acquired pulmonary artery stenosis is scarce in the pediatric population. Most cohorts include a myriad of anatomies and associated conditions.MethodIn order to establish objective performance criteria, we performed a retrospective review of all patients who underwent unilateral pulmonary artery stenting in biventricular physiology at three centers from June 2006 to June 2011.ResultsFifty‐eight patients received 60 stents with Palmaz Genesis stent used most commonly (78%). Average age at implantation was 10.4 ± 10.3 years and weight 31.6 ± 21.8 kg. The immediate success rate was 98%, with improvement in minimal diameter from 5.1 ± 2 cm to 10.6 ± 3 cm (P < 0.01). There were 10 complications (7 major and 3 minor) and no acute mortality. One‐year follow‐up studies were available in 48 patients (83%), including echocardiogram (60%), catheterization (28%), MRI (29%), and lung perfusion (31%). Follow‐up echocardiogram showed mild increase in stent gradient, from 5.7 ± 6.7 mm Hg post‐procedure to 17.1 ± 11.7 mm Hg. Follow‐up catheterization showed no significant change in minimal stent diameter (8.8 ± 2.6 to 7.8 ± 2.3 mm), gradient (7.7 ± 8.4 to 12.6 ± 12.2 mm Hg), or right ventricular pressures (43.7 ± 9 to 47.7 ± 10.5 mm Hg). Nine patients (16%) underwent scheduled stent redilation over a period of 12 days to 25 months.ConclusionIn conclusion, stent implantation shows excellent immediate and 1‐year follow‐up results with maintenance of improved caliber of the stented vessel and lowered right ventricular systolic pressures. © 2014 Wiley Periodicals, Inc.
Endotherapy for and tailored approaches to treating GERD, and refractory GERD
Locke, G. Richard, Horwhat, John D., Mashimo, Hiroshi , Savarino, Edoardo , Zentilin, Patrizia , Savarino, Vincenzo , Armbruster, Steven, Wong, Roy K.H., Moawad, Fouad J. , Zerbib, Frank , Savarino, Edoardo

Annals of the New York Academy of Sciences | June 6, 2014 | Volume: 1300 | Issue: 1 | Pages: 166-186

10.1111/nyas.12240 | PMID 24117641 Get It

This paper presents commentaries on how endoluminal antireflux procedures compare to laparoscopic fundoplication; new endoscopic procedures being studied to treat refractory gastroesophageal reflux disease (GERD); the new Stretta; the relationship between obesity and proton pump inhibitor (PPI) resistance; data concerning acid hypersensitivity and sensory receptors (vallinoid, TRPV1) causing refractory GERD; whether microscopic esophagitis is relevant in determining symptoms of non‐erosive reflux disease (NERD); how concomitant functional gastrointestinal disorders affect the PPI response in NERD; the evidence that a functional esophagus is associated with inflammatory bowel syndrome (IBS); the role of GABA agonists in the treatment of refractory GERD; the role of biofeedback and antidepressants in refractory GERD; and endoluminal fundoplication using the EsophyX device.
SCAI expert consensus statement for advanced training programs in pediatric and congenital interventional cardiac catheterization
Armsby, Laurie B., Beekman, Robert H., Fagan, Thomas E. , Hagler, Donald J. , Hijazi, Ziyad M. , Holzer, Ralf J. , Ing, Frank F. , Kreutzer, Jacqueline , Levi, Daniel S. , Moore, Phillip, Mullins, Charles E., Ruíz, Carlos , Vincent, Robert, Benson, Lee N. , LANG, PETER J. , Latson, Larry , Moore, Phillip

Catheterization and Cardiovascular Interventions | May 29, 2014 | Volume: 84 | Issue: 5 | Pages: 779-784

10.1002/ccd.25550 | PMID 24890705 Get It

Pediatric and Congenital Interventional Cardiology is the practice of catheter‐based techniques that improve cardiac physiology and circulation through the treatment of heart disease in children and adults with congenital or acquired heart defects. Over the last decade, and since last published training guidelines for pediatric cardiac catheterization and interventional cardiology were published in 2005 [1] the field of Pediatric and Congenital Cardiac Catheterization has evolved into a predominantly interventional discipline. As there is no sub‐specialty certification for interventional cardiac catheterization in pediatrics, the Congenital Heart Disease Committee of the Society of Cardiovascular Angiography and Interventions has put together this consensus statement for advanced training in pediatric and congenital interventional cardiac catheterization. The statement puts forth recommendations for program infrastructure in terms of teaching, personnel, equipment, facilities, conferences, patient volume and trainee assessment. This is meant to set a standard for training programs as well as giving applicants a basis on which to judge and compare programs. © 2014 Wiley Periodicals, Inc.
Risk of myocardial infarction and stroke in bipolar disorder: a systematic review and exploratory meta‐analysis
Prieto, Miguel L. , Cuéllar‐Barboza, Alfredo B. , Roger, Véronique L. , Bellivier, Frank , Leboyer, Marion , Frye, Mark A. , Bobo, William V. , West, Colin P. , Bellivier, F , Cuellar-Barboza, Alfredo , Leboyer, Marion

Acta Psychiatrica Scandinavica | May 22, 2014 | Volume: 130 | Issue: 5 | Pages: 342-353

10.1111/acps.12293 | PMID 24850482 Get It

ObjectiveTo review the evidence on and estimate the risk of myocardial infarction and stroke in bipolar disorder.MethodA systematic search using MEDLINE, EMBASE, PsycINFO, Web of Science, Scopus, Cochrane Database of Systematic Reviews, and bibliographies (1946 – May, 2013) was conducted. Case‐control and cohort studies of bipolar disorder patients age 15 or older with myocardial infarction or stroke as outcomes were included. Two independent reviewers extracted data and assessed quality. Estimates of effect were summarized using random‐effects meta‐analysis.ResultsFive cohort studies including 13 115 911 participants (27 092 bipolar) were included. Due to the use of registers, different statistical methods, and inconsistent adjustment for confounders, there was significant methodological heterogeneity among studies. The exploratory meta‐analysis yielded no evidence for a significant increase in the risk of myocardial infarction: [relative risk (RR): 1.09, 95% CI 0.96–1.24, P = 0.20; I2 = 6%]. While there was evidence of significant study heterogeneity, the risk of stroke in bipolar disorder was significantly increased (RR 1.74, 95% CI 1.29–2.35; P = 0.0003; I2 = 83%).ConclusionThere may be a differential risk of myocardial infarction and stroke in patients with bipolar disorder. Confidence in these pooled estimates was limited by the small number of studies, significant heterogeneity and dissimilar methodological features.